JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
Status:
Recruiting
Trial end date:
2023-11-17
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the
treatment of advanced solid tumors with MAPK pathway mutations, including mutations that
cause MAPK pathway hyperactivation.